Cocrystal Pharma, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cocrystal Pharma, Inc. (COCP) on April 1, 2025, covering the date of the earliest event reported as March 31, 2025. The filing serves as an administrative correction to the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2024.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report contains no financial performance data.
Material Changes
There are no material changes to financial results or operations reported. The sole material action is the submission of a corrected auditor's consent (Exhibit 23.1) to reference the Company's effective registration statement on Form S-3 (No. 333-271883), which was previously omitted from the consent filed with the Form 10-K.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is strictly procedural regarding the correction of an exhibit.
Key Facts for Investor Verification
- The filing corrects an omission in the auditor's consent (Weinberg & Company) regarding the Form S-3 registration statement.
- The corrected consent is incorporated by reference into the Registration Statement.
- The report was signed by James Martin, Chief Financial Officer and Co-Chief Executive Officer.
- No new financial data or operational updates are disclosed in this specific 8-K.